ArthritoMab™ Antibody Cocktail - Induce disease in 48 hours

For many years, the Collagen Induced Arthritis (CIA) model has been the traditional model used for evaluating compounds in a model of Rheumatoid Arthritis. The model however, presents many challenges to scientists, which led the search for an alternative model using a cocktail of collagen II antibodies - the Collagen Antibody Induced Arthritis Model (CAIA or ACAIA).

Challenges with the CIA model:

Length of Model
The CIA model can extend out 42 or more days. The available and limited facility space is blocked with animals waiting to exhibit disease symptoms. Compounds with a prophylactic regime will require large amounts of material prohibiting the use of expensive positive controls.

Disease Incidence and Severity.
It is not uncommon for disease incidence to be 75% or less in the CIA model, requiring a larger group size. The severity of disease can also increase as the study continues making the correct assessment of compounds not always possible.

Non-synchronized Disease Onset.
Animals exhibit disease symptoms at different rates, which complicates individual treatment schedules or requires the start of treatment when a certain percentage of animals begin to show disease. Statistical analysis of the study can also more challenging.

 

 

The CAIA model using the ArthritoMab™ Antibody Cocktail presents a real alternative to the CIA model. Read more about the advantages of the CAIA model.